Skip to main content
. 2020 Apr 8;10:6083. doi: 10.1038/s41598-020-63180-8

Figure 6.

Figure 6

Changes in circulating HPV-DNA levels (copies/ml) in four metastatic patients during treatment. Disease was assessed using whole-body CT scans with SD denoting stable radiological disease and PD denoting radiological progressive disease according to RECIST 1.1 criteria with specific tumour response evaluation measurements as below. (A) Patient #B005: SD was defined by 0% change to sum of diameters of target lesions according to RECIST 1.1. The patient received programmed cell death-1 (PD-1) inhibitor immunotherapy. (B) Patient #B010: PD was defined by the appearance of a new target lesion according to RECIST 1.1. Patient received treatment of radiation to the primary base of tongue cancer. C) Patient #B017: SD was defined as a 9% increase in the sum of diameter of target lesions according to RECIST 1.1. The patient received PD-1 inhibitor based immunotherapy. (D) Patient #B023: SD was defined by a 17% increase in the sum of diameters of the target lesions according to RECIST 1.1. The patient received PD-L1 inhibitor immunotherapy.